Table 2.

Treatment Effect of Primary and Secondary Outcome Measures

Outcome Measure	SML Treatment (n = 37)	Spironolactone Treatment (n = 39)	χ2/t	P
Resolution of SRF, n (%)			2.03	0.362
Total	22 (59.5)	17 (43.6)
Partial	8 (21.6)	13 (33.3)
None	7 (18.9)	9 (23.1)
Resolution time of SRF (months), mean ± SD	1.45 ± 1.01	1.39 ± 1.24	0.18	0.855
Number of treatments required to be effective, mean ± SD	1.45 ± 0.51	—	—	—
Resolution of SRF at 1 month, n (%)			0.02	0.890
Yes	12 (27.9)	12 (29.3)
No	31 (72.1)	29 (70.7)
Recurrence of SRF within 6 months, n (%)	2 (9.1) (n = 22)	6 (35.3) (n = 17)	—	0.059
BCVA, mean ± SD
At first evaluation visit	0.37 ± 0.40	0.37 ± 0.40	—	0.651
At final evaluation visit	0.38 ± 0.44	0.43 ± 0.43	—	0.430
SRF, mean ± SD
Height (µm)
At first evaluation visit	111.45 ± 82.69†	99.50 ± 73.85	—	0.348
At final evaluation visit	55.07 ± 72.52†	85.93 ± 90.55†	—	0.475
Longest diameter (µm)
At first evaluation visit	2497.45 ± 1838.48	1802.91 ± 1287.82†	—	0.082
At final evaluation visit	1244.03 ± 1571.81†,‡	1679.57 ± 1539.48†	—	0.920
Area (mm2)
At first evaluation visit	0.21 ± 0.29	0.12 ± 0.12	—	0.036*
At final evaluation visit	0.08 ± 0.12†	0.13 ± 0.19	—	0.202
CRT
At first evaluation visit	279.79 ± 110.69†	266.43 ± 89.82	—	0.357
At final evaluation visit	222.15 ± 94.90†	257.27 ± 102.28†,‡	—	0.135

^*Significant differences were found between the SML group and the spironolactone group.

^†Significant differences compared to the baseline data.

^‡Significant differences were found compared to the first evaluation visit.